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Abstract
Background: Out-of-hospital cardiac arrest (OHCA) frequently occurs in the early phase of acute myo-
cardial infarction (MI). Survivors require percutaneous coronary intervention (PCI) with concomitant 
dual antiplatelet therapy. Target temperature management, including mild therapeutic hypothermia 
(MTH), should be applied in comatose patients after resuscitation. However, an increased risk of stent 
thrombosis in patients undergoing hypothermia is observed. The aim of this study was to assess the 
impact of MTH on pharmacokinetics of ticagrelor in cardiac arrest survivors with MI treated with 
MTH and PCI. 
Methods: In a prospective, observational, single-center study pharmacokinetics of ticagrelor were 
evaluated in 41 MI patients, including 11 patients after OHCA undergoing MTH (MTH group) and 
30 MI patients without OHCA and MTH (no-MTH group). Blood samples were drawn before admin-
istration of a 180 mg ticagrelor loading dose, and 30 min, 1, 2, 4, 6, 12, and 24 h after the loading dose. 
Results: In patients treated with MTH total exposure to ticagrelor during the first 12 h after the load-
ing dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH 
group (AUC(0–12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 
vs. 1568 ± 784 ng/mL, p = 0.0002). Time to achieve maximal ticagrelor plasma concentration was 
also delayed in the MTH group (tmax for ticagrelor: 12 [6–24] vs. 4 [2–12] h, p = 0.01). 
Conclusions: Bioavailability of ticagrelor was substantially decreased and delayed in MI patients 
treated with MTH after OHCA.
Trial registration: ClinicalTrials.gov Identifier: NCT02611934 (Cardiol J XXXX; XX, X: xx–xx)
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Introduction
Out-of-hospital cardiac arrest (OHCA) fre-
quently occurs in the early phase of acute myocar-
dial infarction (MI). OHCA survivors presenting 
symptoms of acute MI require primary percutane-
ous coronary intervention (PCI) with concomitant 
dual antiplatelet therapy (DAPT), including acetyl-
salicylic acid (ASA) and a P2Y12 receptor inhibitor 
[1–4]. Early administration of antiplatelet agents is 
necessary as the highest risk of stent thrombosis 
was reported within the early phase after stent 
implantation [5]. Ticagrelor and prasugrel are 
the preferred P2Y12 inhibitors in this clinical set-
ting [6–11]. In patients remaining in a coma after 
resuscitation targeted temperature management 
should be applied with a constant core temperature 
between 32°C and 36°C [12]. 
It has been shown that plasma concen-
trations of ticagrelor and its active metabolite 
(AR-C124910XX) are diminished in patients with 
ST-segment elevation MI. This effect is even more 
pronounced with concomitant morphine adminis-
tration [13–19]. In survivors of OHCA due to MI 
additional factors including mild therapeutic hypo-
thermia (MTH) may further impede ticagrelor’s 
bioavailability [20–22]. The decreased antiplatelet 
effect of ticagrelor caused by hindered pharma-
cokinetics might be responsible for an increased 
risk of stent thrombosis in resuscitated patients 
undergoing MTH despite DAPT [23, 24].
Thus, the present study was designed [21] 
and performed using a prospective observational 
approach to assess pharmacokinetics of ticagrelor 
in MI patients after OHCA treated with primary 
PCI and MTH. 
Methods
The study was designed and performed as 
a phase IV, single-center, investigator-initiated, 
prospective, observational trial aimed to com-
pare pharmacokinetics of ticagrelor between MI 
patients after OHCA treated with primary PCI 
and MTH (MTH group) and MI patients without 
OHCA treated with primary PCI (no-MTH group). 
The inclusion as well as exclusion criteria for both 
groups have been previously published [21]. 
Mild therapeutic hypothermia was defined as 
a body core temperature below 34°C, with a target 
temperature of 33°C. In order to reach the target 
temperature and maintain it over subsequent 24 h, 
intravascular cooling supported by cold saline (4°C) 
infusion and external cooling at the induction phase 
of MTH were used. The MTH procedure applied in 
this study has also been previously described [21].
All study participants received treatment 
according to the European Society of Cardiol-
ogy guidelines. All patients included in the trial 
received a 300 mg loading dose (LD) of plain ASA 
and a 180 mg LD of ticagrelor in integral tablets 
administered through a nasogastric tube in the 
MTH group, and orally in the no-MTH group. 
The study was conducted in accordance 
with the Declaration of Helsinki and Good Clini-
cal Practice guidelines and was approved by the 
Ethics Committee of The Nicolaus Copernicus 
University in Torun, Collegium Medicum in 
Bydgoszcz (approval number KB 339/2015). 
All MI patients without MTH provided written, 
informed consent to participate in the study 
before enrollment, as additional blood sampling 
was required.  In patients treated with MTH 
due to OHCA it was not possible to obtain in-
formed consent, however these patients did 
not require additional sampling outside the 
standard protocol of MTH monitoring. This is 
a sub-study of the Mild Therapeutic Hypothermia 
for Patients with Acute Coronary Syndrome and 
Cardiac Arrest Treated with Percutaneous Coro-
nary Intervention (UNICORN) study (ClinicalTri-
als.gov Identifier: NCT02611934).
Endpoints
The primary endpoint of this study was the 
area under the plasma concentration-time curve 
(AUC(0–12)) for ticagrelor during the first 12 h af-
ter administration of LD. Secondary endpoints 
included AUC(0–12) for AR-C124910XX, AUC(0-6) for 
ticagrelor and AR-C124910XX, maximum concen-
tration of ticagrelor and AR-C124910XX for 12 h 
(Cmax12), and time to Cmax (tmax) for ticagrelor and AR-
C124910XX, plasma concentrations of ticagrelor 
and AR-C124910XX at baseline, and 30 min, 1, 2, 
4, 6, 12, and 24 h after ticagrelor LD.
Evaluation of pharmacokinetics
Blood samples for pharmacokinetic evaluation 
were drawn before administration of a 180 mg 
ticagrelor LD, and 30 min, 1, 2, 4, 6, 12, and 24 h 
after LD. Ticagrelor and AR-C124910XX plasma 
concentrations were analyzed using liquid chroma-
tography coupled with tandem mass spectrometry. 
Analysis was performed using Shimadzu UPLC 
Nexera X2 system consisting of LC-30AD pumps, 
SIL-30AC Autosampler, CTO-20AC column oven, 
FCV-20-AH2 valve unit, and DGU-20A5R degasser 
coupled with Shimadzu 8030 ESI-QqQ mass spec-
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trometer. Lower limits of quantification were 4.69 
ng/mL for both ticagrelor and AR-C124910XX [25].
Statistical analysis 
All calculations were performed using Sta-
tistica 13.0 package (StatSoft, Tulsa, OK, USA). 
Continuous variables are presented as means ± 
standard deviation and median with quartiles. For 
categorical variables, counts with percentages have 
been used. Due to non-normal data distribution (as 
verified with the Shapiro-Wilk test), comparisons 
between both groups at each measurement point 
were performed with the Mann-Whitney test. For 
comparison of categorical variables, the c2 test or 
the Fisher exact test was applied as appropriate. In 
all cases p values ≤ 0.05 were considered significant.
Table 1. Characteristics of patients enrolled in the study group — mild therapeutic hypothermia (MTH) 
and control group (no-MTH).
MTH group (n = 11) No-MTH group (n = 30) P
Gender, male 73% (8) 80% (24) NS
Age [years] 62.0 ± 11.9 64.4 ± 10.3 NS
History of:
Coronary artery disease 27% (3) 20% (6) NS
Acute myocardial infarction 27% (3) 13% (4) NS
PCI 27% (3) 20% (6) NS
CABG 0% (0) 0% (0) NS
Heart failure 9% (1) 0% (0) NS
Arterial hypertension 54.5% (6) 47% (14) NS
Stroke 9% (1) 0% (0) NS
Smoking 45.5% (5) 60% (18) NS
Acute myocardial infarction:
STEMI 54.5% (6) 60% (18) NS
NSTEMI 45.5% (5) 40% (12)
Number of vessels diseased:
1 36.4% (4) 27 % (8) NS
2 18.2% (2) 43% (13)
3 45.5% (5) 30% (9)
TIMI before PCI:
0 45.5% (5) 40% (12) NS
1 27% (3) 6.6% (2)
2 9% (1) 6.6% (2)
3 18.2% (2) 47% (14)
TIMI after PCI:
0 0% (0) 0% (0) NS
1 0% (0) 3.3% (1)
2 0% (0) 0% (0)
3 100% (11) 96.7% (29)
Number of used stents:
0 0% (0) 3.3% (1) NS
1 54.5% (6) 70% (21)
2 36.4% (4) 20% (6)
3 or more 9% (1) 6.6% (2)
Echocardiography:
LVEF [%] 34.0 ± 11.6 45.5 ± 7.9 0.003
CABG — coronary artery bypass grafting; LVEF — left ventricular ejection fraction; NS — non significant; NSTEMI — non-ST-segment eleva-
tion myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction; TIMI — Throm-
bolysis in Myocardial Infarction
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Results 
Overall 43 MI patients were included in the 
study. There were no significant differences in 
baseline characteristics between both groups, 
except higher left ventricular ejection fraction in 
the no-MTH group (Table 1). Initially, 13 patients 
were enrolled into the MTH group, however com-
plete data (results from all study time-points) were 
available for only 7 patients, as 4 of them had died 
before 24 h from the beginning of the MTH proce-
dure. Additionally, 2 patients from MTH group were 
excluded from the analysis of the primary end point 
due to hemolysis in blood samples that precluded 
complete pharmacokinetic evaluation. Ventricular 
fibrillation was the first recorded rhythm during 
cardiac arrest in all 13 patients. The no-MTH group 
consisted of 30 MI patients without OHCA treated 
with primary PCI. 
Analysis of bioavailability of ticagrelor and 
AR-C124910XX revealed pronounced differences 
between compared groups (Fig. 1). Total exposures 
to both ticagrelor and AR-C124910XX within the 
first 12 h after LD administration, as measured 
by the AUC(0–12) was significantly lower in MTH 
group vs. no-MTH group for ticagrelor (AUC(0–12): 
3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, corre-
sponding to a difference of 61%, p = 0.01), while 
no difference for AR-C124910XX was present 
(AUC(0–12): 1195 ± 1022 vs. 1963 ± 1726 ng·h/mL, 
difference: 40%, p = 0.3). The observed differ-
ences were more pronounced during the first 6 h 
after ticagrelor LD (AUC(0–6) for ticagrelor: 1012 
± 981 vs. 4487 ± 3608 ng·h/mL, difference: 77%, 
p = 0.01; AUC(0–6) for AR-C124910XX: 253 ± 281 
vs. 922 ± 980 ng·h/mL, difference: 73%, p = 0.06). 
The maximal plasma concentration of ticagrelor 
was lower in MTH group vs. no-MTH group 
(Cmax for ticagrelor: 475 ± 353 vs. 1568 ± 784 ng/mL, 
p = 0.0002), whereas there were no differences in 
maximal concentration of the metabolite between 
the groups (Cmax for AR-C124910XX: 203 ± 121 
vs. 337 ± 186 ng/mL; p = 0.1). Time to achieve 
maximal plasma concentrations was delayed for 
both ticagrelor and AR-C124910XX in MTH group 
vs. no-MTH group (tmax for ticagrelor: 12 [6–24] vs. 
4 [2–12] h, p = 0.01; tmax for AR-C124910XX: 18 
[12–24] vs. 4 [4–12] h, p = 0.01) (Fig. 1). 
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Figure 1. The exposures to ticagrelor (A) and AR-C124910XX (B) within 24 h after the administration of ticagrelor load-
ing dose (180 mg). Only patients with complete data were included; MTH — mild therapeutic hypothermia.
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Comparison of plasma concentrations of ti-
cagrelor in consecutive time-points showed sig-
nificant discrepancy between the groups with 
higher drug concentrations seen in no-MTH group, 
starting from the first hour after administration 
of ticagrelor LD (Fig. 2). The difference reached 
level of statistical significance at 2, 4 and 6 h post-
LD (no-MTH group vs. MTH group, respectively: 
882.45 ± 1041.77 vs. 70.36 ± 118.70 ng/mL, 
p = 0.049; 904.43 ± 758.31 vs. 183.41 ± 255.35 ng/mL, 
p = 0.005; 834.58 ± 595.51 vs. 382.09 ± 329.72 
ng/mL, p = 0.036). Higher concentrations of 
AR-C124910XX in no-MTH group were present up 
to 6 h (Fig. 3), and this difference was significant at 
Figure 3. Plasma concentrations of AR-C124910XX over in mild therapeutic hypothermia (MTH) group (n = 11) vs. 
no-MTH group (n = 30). All available data presented.
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Figure 2. Plasma concentrations of ticagrelor over in mild therapeutic hypothermia (MTH) group (n = 11) vs. no-MTH 
group (n = 30). All available data presented.
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2 and 4 h (no-MTH group vs. MTH group, respec-
tively: 155.25 ± 223.16 vs. 7.10 ± 22.46 ng/mL, 
p = 0.04; 218.82 ± 219.14 vs. 41.67 ± 69.12 ng/mL, 
p = 0.015). 
Moreover, additional analysis revealed that 
the proportion of plasma concentration of 
AR-C124910XX to concentration of ticagrelor 
changed during observation according to different 
patterns in MTH group vs. no-MTH group. This 
proportion was lower in MTH group in comparison 
to no-MTH group during the first 2 h. The similar 
ratios were observed 4 h after administration of 
ticagrelor LD (22.7% vs. 24.2%), and later this 
proportion was higher in MTH group up to the end 
of observation, achieving the highest difference at 
6 h (80.1% vs. 22.7%). Of note, none of 4 patients 
who died (all from MTH group) during the study 
observation period (24 h) had detectable plasma 
ticagrelor or AR-C124910XX.
Discussion
According to available research, this is the 
first study assessing the impact of OHCA treated 
with MTH on pharmacokinetics of ticagrelor in MI 
patients undergoing primary PCI.
Impaired bioavailability of ticagrelor expressed 
by lower total exposure, lower maximal plasma 
concentration and delayed maximal plasma concen-
tration of the drug in patients undergoing MTH and 
PCI due to OHCA in the course of MI in comparison 
with patients treated with primary PCI for uncom-
plicated MI, advocates impaired gastrointestinal 
absorption of ticagrelor in critically ill patients 
undergoing therapeutic hypothermia. Moreover, 
presence of different AR-C124910XX formation 
rates between compared groups suggests potential 
diversity in drug metabolism and/or elimination. 
Recently, it has been reported that the presence of 
STEMI and diabetes are connected with impaired 
metabolism of ticagrelor during the first 6 h after 
ticagrelor LD for acute coronary syndrome [26]. In 
the current trial clear differences were observed in 
ticagrelor’s active metabolite formation between 
patients with and without OHCA treated with 
MTH, however small the size of cardiac arrest,  the 
survivor group did not allow formal conclusions to 
be drawn. This important issue requires clarifica-
tion in further research. 
Straub et al. [27] showed that adenosine 
diphosphate (ADP) plays a central role in hypo-
thermia-induced platelet activation during hypo-
thermia, suggesting that inhibition of ADP recep-
tor binding has the potential to protect platelets 
against hypothermia-induced activation. However, 
in previously published studies insufficient efficacy 
of clopidogrel in patients undergoing MTH after 
OHCA was reported [28–32]. It was mostly ex-
plained by accelerated platelet turnover, increased 
platelet activation as well as by decreased bioavail-
ability of clopidogrel due to its impaired absorption 
and diminished active metabolite generation [1, 28, 
33, 34]. The effect of ticagrelor and prasugrel in 
this clinical setting is not clear [35].
The high rate of stent thrombosis observed in 
some studies in resuscitated MI patients treated 
with MTH and primary PCI may be caused by 
insufficient inhibition of P2Y12 platelet receptors 
[23, 24, 36–40]. In an observational study pub-
lished by Gouffran et al. [24], 10.9% of OHCA 
survivors treated with MTH had stent thrombosis 
(the latter occurred in 4.2% of patients on clopi-
dogrel, 18.2% on prasugrel, and 16.7% on ticagre-
lor). Jiménez-Brítez et al. [37] reported in-hospital 
stent thrombosis in 7.1% of patients, exclusively 
those treated with clopidogrel (11.4%), while no 
stent thrombosis occurred in patients on ticagre-
lor or prasugrel. Joffre et al. [23] found cardiac 
arrest treated with MTH to be an independent 
risk factor for confirmed stent thrombosis (odds 
ratio = 12.9; 95% confidence interval 1.3–124.6, 
p = 0.027) regardless of the type of P2Y12 antago-
nist. Penela et al. [36] reported clinical resistance 
to clopidogrel with an extremely high incidence 
of acute stent thrombosis. In a small group of 
11 MTH patients enrolled in the study, stent 
thrombosis occurred in 5 (31.2%) cases, while 
2 other patients experienced other thrombotic 
complications. Of note, most of the thrombotic 
complications occurred long after rewarming [36]. 
It is not clear if hypothermia itself or rather 
centralization of circulation in critically ill patients 
is responsible for impairment of ticagrelor absorp-
tion. The results of the ISAR-SHOCK registry 
demonstrated a weaker antiplatelet effect in shock 
patients receiving either clopidogrel or prasugrel 
without hypothermia [41]. This observation may 
suggest that the impaired effect of oral P2Y12 inhibi-
tors in OHCA is related not only to hypothermia, 
but rather multifactorial [41, 42]. Regardless of 
what the exact mechanisms of ineffectiveness of 
these drugs are, intravenous infusion of a short-
acting P2Y12 receptor antagonist — cangrelor 
— is capable of inhibiting life-threatening platelet-
mediated prothrombotic events in the setting of 
MTH. This innovative pharmacological strategy 
could significantly improve the safety of MTH 
[43–45]. Infusion of glycoprotein IIb/IIIa inhibitors 
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is another therapeutic option allowing patients to 
overcome shortcomings of oral antiaggregatory 
agents, it is however, associated with markedly 
increased risk of bleedings [46–49]
Limitations of the study
The main limitation of the present study, which 
is similar to all previously published reports, is the 
low number of enrolled OHCA survivors treated 
with MTH and primary PCI. This did not permit 
the evaluation of clinical end points. Moreover, it 
was not possible herein, to differentiate the impact 
of MTH from consequences of local circulatory 
disorders. Also, the current trial did not evaluate 
pharmacodynamics of ticagrelor.
Nevertheless, careful monitoring of plasma 
concentrations of ticagrelor and AR-C124910XX at 
multiple time-points allowed us to demonstrate ex-
tensive differences in drug bioavailability between 
OHCA patients treated with MTH and primary 
PCI and patients with uncomplicated MI treated 
with primary PCI. Observations in the present 
research provide important evidence which may 
help to elucidate causes of the higher prevalence 
of stent thrombosis and other thrombotic events 
in patients undergoing MTH.
Conclusions
Bioavailability of ticagrelor is substantially 
decreased and delayed in MI patients treated with 
MTH after OHCA compared with patients with 
uncomplicated MI and without OHCA requiring 
MTH. 
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